Teva Pharmaceutical Industries and Samsung Bioepis have announced a new licensing and commercialisation agreement covering two FDA-approved immunology biosimilars in the US, further expanding their existing partnership in the biosimilars market.
Under the agreement, Teva will gain US commercialisation rights to ETICOVO (etanercept-ykro) when the deal closes and will assume commercialisation rights to infliximab-abda in the third quarter of 2027.
Samsung Bioepis will retain responsibility for regulatory oversight and manufacturing of both products. The transaction remains subject to customary closing conditions, including regulatory approvals, and is expected to close by the end of 2026.
The two treatments are biosimilars referencing Enbrel and Remicade respectively and are intended for the treatment of a range of chronic inflammatory and autoimmune diseases.
Richard Francis, President and CEO of Teva, said: “This agreement strengthens our collaboration with Samsung Bioepis and will expand our U.S. immunology portfolio with two additional biologic treatment options.”
He added: “Biosimilars are an important part of our Pivot to Growth strategy, helping us build a stronger portfolio while expanding access to high-quality medicines.”
Francis continued: “Together, we have an opportunity to bring more treatment choices to patients living with chronic inflammatory conditions.”
Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis, explained: “We are delighted to expand our strategic alliance with Teva to strengthen the commercial footprint of our immunology portfolio in the U.S.”
Kim added: “Infliximab-abda has established a proven track record of clinical efficacy and supply reliability since its launch, while ETICOVO represents an FDA-approved therapy poised to broaden treatment choices for patients.”
She continued: “By pairing our dedication to high-quality biologic development and manufacturing with Teva’s commercial reach across U.S. healthcare channels, we aim to ensure uninterrupted treatment continuity for existing patients and bring sustainable value to the US healthcare system.”
The latest agreement builds on several biosimilar partnerships between the companies. In 2025, they agreed a US commercialisation deal for EPYSQLI, while during 2026 they announced agreements covering OPUVIZ in Canada and up to six biosimilar candidates currently in early-stage development.
